Quin is an MD, with further degrees in genetics, mathematics, and computational biology, and a doctorate in systems genomics, from Oxford and Cambridge Universities. He previously founded his first liver drug genomics company, co-steered Oxford University’s single-cell genomics consortium, and most recently founded the Cellular and Systems Genomics department for the leading metabolic biopharma (focused on fatty liver target discovery).